Latest medical treatment for hemangioblastomas in central nervous system

DOI

Bibliographic Information

Other Title
  • 中枢神経系血管芽腫における最新の診療

Abstract

<p>　Central nervous system hemangioblastoma （HB) is a grade 1 tumor classified by the WHO classification and is considered to be benign in nature. It is said that nearly 70% of patients with von Hippel-Lindau (VHL) disease have HB, and it is the most likely disease among VHL diseases. The most common sites of occurrence are the cerebellum, spinal cord, and brainstem, and it often develops as a result of symptoms of increased intracranial pressure (headache, vomiting, etc.) thought to be caused by obstructive hydrocephalus. In VHL disease cases, HB occurs frequently in the spinal cord, and it is often encountered that ADL gradually declines due to worsening of spinal symptoms. The first choice of treatment is surgical removal, but if the risk of removal is high, gamma knife treatment is also performed. Until recently, no effective drug had been approved, but the HIF-2α inhibitor belzutifan was approved by the FDA in August 2021. This article will also outline the treatment system in our department to overcome HB.</p>

Journal

Keywords

Details 詳細情報について

  • CRID
    1390299981563453184
  • DOI
    10.18976/jsht.23.4_127
  • ISSN
    24356808
  • Text Lang
    ja
  • Data Source
    • JaLC
  • Abstract License Flag
    Disallowed

Report a problem

Back to top